Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M110800200 on December 17, 2001

J. Biol. Chem., Vol. 277, Issue 10, 7831-7837, March 8, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
277/10/7831    most recent
M110800200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linnemann, T.
Right arrow Articles by Herrmann, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linnemann, T.
Right arrow Articles by Herrmann, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Activation of RalGDS Can Be Achieved Independently of Its Ras Binding Domain

IMPLICATIONS OF AN ACTIVATION MECHANISM IN Ras EFFECTOR SPECIFICITY AND SIGNAL DISTRIBUTION*,

Thomas LinnemannDagger, Christina Kiel, Peter Herter, and Christian Herrmann§

From the Abteilung Strukturelle Biologie, Max-Planck-Institut für Molekulare Physiologie, Otto-Hahn-Strasse 11, Dortmund 44227, Germany

Received for publication, November 12, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Small GTPases of the Ras family are major players of signal transduction in eukaryotic cells. They receive signals from a number of receptors and transmit them to a variety of effectors. The distribution of signals to different effector molecules allows for the generation of opposing effects like proliferation and differentiation. To understand the specificity of Ras signaling, we investigated the activation of RalGDS, one of the Ras effector proteins with guanine-nucleotide exchange factor activity for Ral. We determined the GTP level on RalA and showed that the highly conserved Ras binding domain (RBD) of RalGDS, which mediates association with Ras, is important but not sufficient to explain the stimulation of the exchange factor. Although a point mutation in the RBD of RalGDS, which abrogates binding to Ras, renders RalGDS independent to activated Ras, an artificially membrane-targeted version of RalGDS lacking its RBD could still be activated by Ras. The switch II region of Ras is involved in the activation, because the mutant Y64W in this region is impaired in the RalGDS activation. Furthermore, it is shown that Rap1, which was originally identified as a Ras antagonist, can block Ras-mediated RalGDS signaling only when RalGDS contains an intact RBD. In addition, kinetic studies of the complex formation between RalGDS-RBD and Ras suggest that the fast association between RalGDS and Ras, which is analogous to the Ras/Raf case, achieves signaling specificity. Conversely, the Ras·RalGDS complex has a short lifetime of 0.1 s and Rap1 forms a long-lived complex with RalGDS, possibly explaining its antagonistic effect on Ras.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Ras is known as a major regulator of cell growth, development, and the cell cycle. Ras binds tightly to GDP or GTP, and this conversion between both nucleotide states is strictly controlled and involves conformational changes in two regions of the protein. Therefore, Ras behaves like a molecular switch. The active GTP state of Ras signals to different protein cascades. In the past Raf, phosphatidylinositol 3-kinase (PI3K1), and members of the RalGDS family were described as effectors of Ras, and a similar relationship is proposed for other proteins like AF6 or Rin (1, 2). Because Ras is tethered to the plasma membrane through its lipid modifications, the effectors are recruited to the plasma membrane.

Ras can initiate different effects like proliferation and differentiation. In many systems Raf signaling via extracellular regulated kinase is sufficient for cell transformation (3). Oncogenic properties are also demonstrated for PI3K and RalGDS, albeit weaker (4, 5), and suppression of these protein functions can partly block transformation by Ras (6, 7). In other primary cells the opposite effects, cell cycle arrest and cell differentiation, are induced by active Ras (8). In the neuroblastoma cell line PC12, the activation of the Raf and PI3K branch of Ras signaling transmits the nerve growth factor signal to finally induce neurite outgrowth (9). In contrast, the RalGDS branch blocks this differentiation and keeps the cell in a proliferative state (10).

Members of the RalGDS family have guanine-nucleotide exchange factor (GEF) activity for RalA and RalB (11). The members of this family, RalGDS, Rgl, and Rlf, have a C-terminal Ras binding domain (RBD). Rgr, another member, was identified as part of a fusion protein, which confers tumor-forming activity on NIH3T3 cells (12).

The small Ras-related GTPase Rap1 was originally identified as a Ras antagonist (13), and this finding was confirmed in other studies (14-19). Recent findings show that direct functions are the control of development and cell morphology (20). The interaction between Rap1 and RalGDS-RBD is the tightest interaction seen for a Ras family member and an effector RBD (21). In reconstituted lipid vesicle systems a stimulation of the RalGDS effector pathway could be achieved and was interpreted as the Rap1-induced co-localization of RalA and RalGDS on the artificial lipid membranes (22). In experiments with COS7 cells it was not possible to demonstrate any stimulatory effect of Rap1 on RalGDS (7). This was interpreted with different localizations of Rap1 and RalA (23). However, other studies have clearly shown that Rap1 is found at the plasma membrane and membranes of specialized vesicles (24-27). Furthermore, RalA is not solely localized at the plasma membrane but is also found in intracellular vesicles (28). Therefore, cellular localizations of Rap1 and Ral do not exclude a functional cascade of Rap1, RalGDS, and Ral. Another explanation for the inability of Rap1 to activate RalGDS could be seen in an activation mechanism as described for Raf kinase (29) and PI3K (30). In such a scenario, RalGDS could be recruited to the plasma membrane by Ras and additionally activated; Rap1 would only be able to bind RalGDS. To test this hypothesis we have analyzed different constructs of RalGDS and demonstrated an RBD-independent activation mechanism, which involves the switch II region of Ras. Kinetic studies support the notion that the Ras switch has evolved to control the association speed of effector complex formation (31). The latter can be reconciled with the finding that the lower affinity interaction between Ras and RalGDS is sufficient for signal transmission. A comparison with other RBDs prompted us to conclude that the high affinity between Rap1 and RalGDS could be important for the inhibition of this signaling branch of Ras.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Plasmids-- pBSK:mRalGDS, containing the RalGDS cDNA from mouse, was kindly provided by Dr. R. A. Weinberg. The whole cDNA, including the 5'-untranslated region was sub-cloned with EcoRI/Aat2 after removal of the 5'-overhang from the Aat2 restriction site into EcoRI/EcoR5-digested pcDNA3 to yield pcDNA3:mRalGDS. The K835A variant of RalGDS was generated according to the PCR mutation protocol of Picard et al. (32).

pcDNA3:RalGDS, which contained a Myc-tag, was obtained with two PCR templates between the primers 5'-GCGGAATTCGCGGCCGCG/5'-CCGGGTACCTATAGGTCCTCCTCGGAGATCAGCTTCTGCTCCATCCTCAGCCTCGG and 5'-CCGGAATTCAGGACCTGGAAGTAGATTGCCAG/5'-CGGGGTACCTCTAGAGGAGGC. Fragments were amplified from pBSK:mRalGDS and sub-cloned via EcoRI/KpnI digestion into pBKS. The first PCR template was ligated in front of the second with EcoRI/EcoO109 yielding an N-terminal construct of RalGDS, which contains the whole 5'-untranslated region, and a c-Myc-tag at the N terminus. The two original Met start codons of RalGDS are deleted in this construct. This fragment was sub-cloned with EcoRI/XbaI digestion into pcDNA3:RalGDS using only the N-terminal XbaI restriction site in pcDNA3:RalGDS.

To generate pcDNA3:RalGDSDelta RBD the XhoI restriction site in pBKS:mRalGDS was removed with a XhoI/SalI digestion followed by religation (= pBKS:mRalGDSDelta XhoI). The RBD was removed from this construct with PstI/Aat2 digestion and an oligonucleotide linker comprising 5'-GCTACAGCGTTAACTAACTCGAGGACGT and 5-CCTCGAGTTAGTTAACGCTGTAGCTGCA was ligated into this plasmid (= pBKS:mRalGDSDelta RBD). Sub-cloning of a fragment from pBKS:mRalGDSDelta RBD to pcDNA3:RalGDS with PshA1/XhoI digestion resulted in pcDNA3:RalGDSDelta RBD.

RalGDS-RBD was introduced into pcDNA3:RalGDSDelta RBD with a PCR fragment amplified from pBKS:mRalGDS between the primers 5'-GGTCTGCAGCTACAGCTC and 5'-CCGCTCGAGTTAGTTAACGGTCCGCTTC. The PCR fragment was then ligated with PstI/XhoI into pBKS:mRalGDSDelta RBD. The resulting pBKS:mRalGDS* does not contain the last 30 amino acids of RalGDS. Sub-cloning a PshA1/XhoI fragment from pBKS:mRalGDS* into pcDNA3:Myc-mRalGDS led to pcDNA3:RalGDS*.

The C terminus from Ki-Ras, including the CAAX box, was attached to the RalGDS sequences via a PCR fragment amplified from ptac:K-ras (provided by Dr. A. Wittinghofer) between the primers 5'-CGCGGATCCGTTAACAAAGATGGTA and 5'-CCGCTCGAGTTACATAATT. The amplified sequence was ligated to pBKS:mRalGDS* and pBKS:mRalGDSDelta RBD between the restriction sites HpaI and XhoI. The CAAX-modified RalGDS sequences were sub-cloned with PshA1/XhoI to pcDNA3:RalGDS to yield pcDNA3:RalGDS*CAAX and pcDNA3:RalGDSDelta RBD-CAAX, respectively.

pMT2:RalA was kindly provided by Dr. G. J. T. Zwartkruis, pSVK3:Ras G12V and the double mutants G12V/Y64W and G12V/E37G in the same expression vector were provided by Dr. C. Block. pcDNA3:Rap1A G12V was obtained from Dr. A. Wittinghofer. All constructs were verified by sequence analysis.

Cell Culture and Transfection Assay-- COS7 cells were grown in DMEM (without pyruvate, with pyridoxin and Glutamax-1, Invitrogen) and 10% FCS (Pan-Biotech). The cells were transfected with activated dendrimers (SuperFect, Qiagen) in 6-cm dishes. 5-6 µg of DNA was diluted with 125 µl of DMEM, and 20 µl of SuperFect reagent was added. The cells were incubated with this transfection solution for 4 h and then incubated in medium with 10% FCS for 24 h. The RalA loading assay was carried out as described previously (5). Briefly, 24 h after transfection the COS7 cells were grown overnight in DMEM with 1.5% FCS. Then the cells were washed with DMEM without serum and incubated in DMEM (without phosphate) containing 0.3 mCi of [32P]orthophosphate for 5 h. The cells were then lysed and the hemagglutinin-tagged RalA immunoprecipitated with the 12CA5 antibody (Roche Molecular Biochemicals) coupled to protein G-Sepharose (Amersham Biosciences, Inc.). The Sepharose resin with the 12CA5 antibody and the precipitated RalA was extensively washed, and the remaining GTP/GDP was eluted. Both guanine nucleotides were separated by TLC with polyethylenimin-cellulose (Merck), and their amounts were quantified by phosphorimaging analysis (Bio-Rad).

Immunofluorescence and Western Blots-- COS7 cells were directly cultured on coverslips and transfected with SuperFect as described above. 1 µg of DNA was used for transfection. After transfection and expression of the constructs, the cells were fixed and incubated with antibodies as described previously (54). For the recognition of c-Myc-tagged RalGDS constructs, the monoclonal 9E10 antibody was employed (Roche Molecular Biochemicals), and for detection of the primary antibody Alexa 594 goat alpha -mouse (Molecular Probes) was used. Fluorescence was observed with a Zeiss confocal microscope at 1-µm z-resolution and ×100 magnification.

Western blotting was performed according to standard procedures with a secondary antibody conjugated to horseradish peroxidase. For the recognition of RalGDS alpha -Myc (Santa Cruz Biotechnologies) alpha -RalGDS-RBD or alpha RG139 (both kindly provided by R. Berdeaux, Berkeley, CA) were used. Detection was carried out with ECL luminescence (Amersham Biosciences, Inc.). Expression levels of RalGDS in the Ral loading assay were determined in separate transfections.

Proteins-- RalGDS-RBD (formerly termed RGF97) and Rap1A were prepared as described by Herrmann et al. (21), and the preparation of Ras is described by Tucker et al. (33). Loading of the Ras proteins with GppNHp (Sigma Chemical Co.) and mantGppNHp, respectively, was performed in a buffer containing 200 mM ammonium sulfate and 2 units of alkaline phosphatase (Roche Molecular Biochemicals) per milligram of protein. mantGppNHp was synthesized according to John et al. (34). In the case of Ras a 2-fold excess of the non-hydrolyzable nucleotide was added, and in the case of Rap1A a 5-fold excess and 10 mM EDTA were added. The solutions were incubated at 20 °C for 1 h. For a last step of purification, all proteins were subjected to size exclusion chromatography (Superdex 75, Amersham Biosciences, Inc.). Protein concentrations were measured using the dye assay as described by Bradford (35). Bovine serum albumin was used for calibration.

In Vitro Assays-- All experiments were carried out in a buffer containing 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2 and 1 mM dithioerythritol. Fluorescence spectra were recorded on a spectrofluorometer (Fluoromax, Spex) at 25 °C with an experimental error smaller than 5% when the spectra were reproduced. For stopped-flow measurements, an SM17 apparatus (Applied Photophysics) was used. Rate constants can reliably be measured up to 500 s-1, because the dead time for the mixing of two solutions is in the range of 1-2 ms. mant nucleotides were excited at 360 nm, and the fluorescence was recorded through a 408-nm cut-off filter. Ras or Rap1A bound to mantGppNHp was mixed with RalGDS-RBD in more than 5-fold molar excess to have pseudo-first order conditions. Binding of effectors to Ras proteins is detectable by a change of the fluorescence of the mant nucleotide as described earlier (31, 36).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Ras G12V-mediated RalGDS Activation Can Be Impaired by a Single Point Mutation within the RBD-- Previous experiments have shown the activation of proteins of the RalGDS family by Ras (11). From the structure of the complex between Ras and RalGDS-RBD, it became evident that K835 (originally termed K48 in the RBD of RalGDS (37)) is one of three major amino acids involved in the complex formation between RalGDS-RBD and Ras proteins (38, 39). The K835A mutation reduced the binding affinities by a factor of >25 and 700 for Ras and Rap1A, respectively. This mutation was tested in the Ral loading assay (Fig. 1). We chose to analyze the ratio of GTP over total guanine nucleotide bound to RalA, because this does not depend on changes in the expression levels of RalA as compared with methods, which detect only the GTP form. RalGDS and its K835A mutant were transiently expressed in COS7 cells together with RalA and a constitutive active version of Ras (Ras G12V). The activity of RalGDS was measured indirectly via the GTP load on immunoprecipitated RalA. In accordance with the results from Urano et al. (7), it is shown that, upon co-expression of RalGDS and RalA in COS7 cells, the GTP content on RalA is significantly increased over the basal GTP content when RalA is expressed either alone, or together with Ras G12V in COS7 cells. However, the 23% GTP bound to RalA in the presence of RalGDS was increased to 37% with Ras G12V. In contrast, the K835A mutant, which was expressed at a slightly higher level than the wild type, was hardly stimulated by Ras G12V. These results underscore the important contribution of the RBD for the stimulation of RalGDS by Ras.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of the mutant RalGDS K835A on the Ras-mediated stimulation of RalGDS. In each experiment 1 µg of pMT2:RalA was transfected. In addition, pcDNA3:RalGDS (WT) and its K835A mutant (1 µg) and pSVK3:RasG12V (3 µg) were co-transfected as indicated. After immunoprecipitation of RalA the bound nucleotides were separated by thin layer chromatography and visualized by phosphorimaging (upper panel). The density counts of the GDP and GTP spots were quantified, and the ratio of bound GTP on RalA was calculated. The mean value and standard deviations from three independent transfections are shown in the lower panel. The insert shows a Western blot of RalGDS and its K835A mutant detected by the monoclonal alpha -RG139 antibody, indicating comparable expression of both constructs. As seen with marker proteins, the 99-kDa RalGDS runs in SDS-PAGE at a molecular mass > 116 kDa. Similar observations were made by Albright et al. (44) and possibly indicate post-translational modifications.

RalGDS Can Be Activated by Ras Independently of Its RBD-- In agreement with recent reports (5, 7) the experiments described above showed that members of the RalGDS family are activated by Ras. Rap was not able to activate RalGDS, although the affinity between both proteins is two orders of magnitude higher than that of RalGDS and Ras (21). To understand the difference between Ras and Rap regarding the activation of RalGDS, we tested whether additional activation steps are involved during the interaction between Ras and RalGDS. To discriminate between recruitment and activation of RalGDS by Ras, different constructs of the exchange factor were used (Fig. 2A). The C-terminal 30 amino acids, which do not belong to the C-terminal RBD fold, were deleted (RalGDS*), and the Ki-Ras CAAX box was attached (RalGDS*CAAX). In addition, the RBD was deleted from RalGDS (RalGDSDelta RBD), and again the Ki-Ras CAAX box was tethered to the newly formed C terminus (RalGDSDelta RBD-CAAX).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of RalGDS variants in COS7 cells. A, the domain organization of RalGDS. It consists of the Ras exchange motif (R), the guanine nucleotide exchange factor motif (GEF), and the Ras binding domain (RBD). For the mutants used in this study the C-terminal alterations are shown. All RalGDS constructs contain a c-Myc tag at the N terminus. B, c-Myc-tagged RalGDS constructs were transiently transfected into COS7 cells, and their localization was probed with the monoclonal alpha -c-Myc antibody 9E10 and a secondary antibody conjugated to the Alexa 594 dye. The immunofluorescence images were obtained by confocal microscopy. The numbering of the images is in accordance with those of the constructs shown in A.

The localization of the different RalGDS constructs was investigated via immunofluorescence with confocal microscopy and compared with the wild type (Fig. 2B). For RalGDS a typical cytosolic stain could be observed in the confocal plane (image 1). A similar staining pattern was seen for the Myc-mRalGDS* and -Delta RBD constructs, indicating that the truncated constructs localize to the same cellular compartments as RalGDS (images 2 and 4). In contrast, when the CAAX-box modified versions of RalGDS were analyzed, a rim stain was observed that demonstrates the artificial recruitment to the plasma membrane (images 3 and 5).

Next, the modified RalGDS constructs were transiently expressed in COS7 cells, and their activity was probed by the determination of the GTP content of co-transfected RalA. In addition, the capability of Ras G12V to stimulate the nucleotide exchange rate of RalA via the RalGDS variants was investigated. In Fig. 3 it is seen that the RalGDS* construct, which lacks the 30 C-terminal amino acids, behaves similarly to RalGDS wild type in Fig. 1, i.e. the GTP content of RalA when co-transfected with WT* can be stimulated from 25% to 35% in the presence of Ras G12V. Western blot analysis demonstrated comparable expression levels of the RalGDS constructs regardless of whether Ras G12V was present or not. RalGDS*CAAX was only moderately stimulated by Ras G12V as well as RalGDS without its RBD. In contrast, deletion of the RBD and artificial recruitment to the plasma membrane resulted in a construct, which was activated by Ras G12V. The latter demonstrates an RBD-independent mechanism of RalGDS activation by Ras.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Activation of RalGDS variants by Ras. A, RBD-independent activation of RalGDS. 1 µg of pMT2:RalA was co-transfected with the indicated RalGDS and Ras expression vectors (1 µg each). The GTP content of RalA was quantified after immunoprecipitation as described in Fig. 1. The experiments were repeated three times, and the mean and standard deviation of the GTP content of Ral are given. The Western blot (WB) shows the expression levels of RalGDS probed with the alpha -Myc antibody. B, the switch II region of Ras is involved in the activation of RalGDS. As under A, pMT2:RalA was co-transfected with RalGDSDelta RBD-CAAX as indicated. In addition, Ras G12V and Ras G12V, Y64W mutants were co-expressed and the GTP content of RalA was quantified. The data show a representative experiment from three repetitions.

Ras contains two regions that change their conformations in response to the nucleotide state of the GTPase and are called switch I and switch II. Structural analysis demonstrated that the switch I region is mainly responsible for recognizing the RBD of an effector. The complex structures of PI3K and Ras clearly show that the switch II region makes contacts with the kinase domain and helps to elevate the basal activity of the lipid kinase (30). Encouraged by these findings, we tested an activated mutant of Ras in this region (Ras G12V, Y64W) in the RalGDS activation assay (Fig. 3B). This mutant did not stimulate RalGDSDelta RBD-CAAX as efficiently as did Ras G12V, indicating the involvement of the switch II region in the activation of RalGDS.

Influence of Rap1 on the Activation of RalGDS-- Rap1 had been described as an antagonist of Ras (13-19). Therefore, we tested whether it can block the Ras-mediated activation of RalGDS. When constitutively active Rap1A G12V was transiently transfected together with RalGDS-WT* or RalGDSDelta RBD-CAAX, it is seen that the RBD is required for a decrease of the exchange activity (Fig. 4). The block of signal transmission was seen in the non-stimulated and Ras G12V-stimulated case. Western blot analysis of the RalGDS expression levels showed comparable levels in all assays. The presence of the RBD is crucial for an Rap1-mediated effect on Ras signaling via RalGDS.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Influence of Rap1 on the Ras and RalGDS-mediated nucleotide exchange on RalA. 1 µg of pcDNA3:RalGDS* and 1 µg of pcDNA3:RalGDSDelta RBD-CAAX, respectively, was co-transfected with 1 µg of pMT2:RalA into COS7 cells. In addition, pSVK3:Ras G12V and pcDNA3:Rap1A G12V (1 µg) were co-transfected. The nucleotide load on RalA was determined as described in Fig. 1. The columns represent the mean and standard deviations of the GTP content on RalA of three independent experiments. Note that the data for the transfections without Rap1A G12V were taken from Fig. 3 to compare the influences of Rap1 on RalGDS activity. The Western blot (WB) shows the expression levels of RalGDS probed with the alpha -Myc antibody.

Dynamics of the Interaction between RBDs and Ras Proteins-- Depending on its GTPase binding partner, RalGDS is either activated or inhibited. Rap seems to sequester RalGDS into an inactive complex. To further understand the result of a parallel activation of Ras and Rap, we investigated the specificity of the RalGDS-RBD with stopped-flow experiments. To follow the binding between the GTPases and RalGDS-RBD, we employed a fluorescent nucleotide (mantGppNHp) as described previously (31, 36). Upon binding of RalGDS-RBD to Ras or to Rap complexed with mantGppNHp, a decrease in fluorescence was observed (Fig. 5, upper panel). The RalGDS-RBD concentration was in more than 5-fold molar excess over the GTPases; therefore, the fluorescence traces could be fitted according to pseudo-first order kinetics by a single-exponential equation yielding the observed rate constant kobs. The bimolecular association constant kon was obtained from the slope of the linear regression of kobs plotted versus RalGDS-RBD concentration (Table I). The dissociation rate constant koff corresponds to the intercept value. koff is 10 s-1 for the dissociation of the Ras·RalGDS-RBD complex and close to zero for the Rap·RalGDS system. To ensure that determination of kon is not obscured by saturation at higher RalGDS-RBD concentrations, only concentrations up to 15 µM RBD were included in the calculations above. Similar to other effector RBDs (31, 36), saturation of the binding kinetics was observed at higher concentrations (Fig. 5, lower panel), and these data can be described with the hyperbolic equation 1 yielding k+2 and K1. k-2 corresponds to koff from the linear approach at low concentrations (see above),
k<SUB><UP>obx</UP></SUB>=<FR><NU>k<SUB><UP>+2</UP></SUB></NU><DE>1+K<SUB>1</SUB>/[<UP>RBD</UP>]</DE></FR>+k<SUB><UP>−2</UP></SUB> (Eq. 1)
As with other effectors like AF6- and Raf-RBD (31, 36), this behavior may be interpreted as a two-step complex formation. For the interaction of Ras·mantGppNHp and RalGDS-RBD, the dissociation equilibrium constant for the first step is K1 = 61 µM. The overall rate is limited to 300 s-1 by the rate constant k2 for the second step, which presumably corresponds to a conformational rearrangement. These observations reflect the structural similarity of effector·RBD/Ras complexes. The experimental error for the k2 value is estimated to 10%, whereas for K1 the error is 20%, because errors, both in the fit and in the determination of the concentration, must be considered. For the Rap1·RalGDS-RBD system, no saturation of kobs was detected up to rates of 500 s-1 at 100 µM RalGDS-RBD, suggesting a much weaker initial complex.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   Kinetics of Ras·RalGDS-RBD interaction. A, the association of 2.5 µM RalGDS-RBD and 0.5 µM Ras·mantGppNHp was measured at 25 °C by stopped-flow, and an exponential curve was fitted to the data yielding kobs (decreasing fluorescence). The dissociation of a complex of 2.5 µM RalGDS-RBD and 0.5 µM Ras·mantGppNHp was initiated with 60 µM Ras·GppNHp. The resulting change in fluorescence was fitted with an exponential curve to determine koff (increasing fluorescence). The insert shows the change of fluorescence when 0.5 µM Ras were mixed with 50 µM RalGDS-RBD. All spectra were corrected with the buffer blank. 1, Ras·mantGppNHp; 2, Ras·mantGppNHp and RalGDS-RBD; 3, Ras·mantGDP; 4, Ras·mantGDP and RalGDS-RBD. B, saturation of the kobs values at higher RalGDS-RBD concentrations at 10 °C. The curve is the result of a fit to the data according to Equation 1.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Association and dissociation rate constants for Ras and Rap1A interacting with RalGDS-RBD
The KD value is calculated from the ratio of the rate constants. The experimental error on rate constants is 10%. For comparison available data for Raf-RBD and AF6-RBD are included (31, 36).

Due to its small value, the dissociation rate constant of RBD·GTPase complexes cannot be determined precisely from the intercept as described above. Therefore we employed displacement experiments to obtain this value more reliably. The equilibrated complex Ras·mantGppNHp·RalGDS-RBD was rapidly mixed with a large excess (>100-fold) of Ras bound to non-labeled GppNHp to sequester RalGDS-RBD. Under these conditions the change of the fluorescence intensity is governed by the dissociation of RalGDS-RBD from Ras·mantGppNHp, and koff can be derived thereof with a 10% error. The corresponding dissociation rate constant for the Rap1 complex was determined as well.

Table I summarizes the results of the interactions between RalGDS-RBD and Ras or Rap1 at 25 °C and compares them with AF6- and Raf-RBD. Despite the large differences in the KD values, which vary by a factor of 400, it can be seen that the association rate constants lie close together (within a 5-fold variation). The differential affinities of the complexes are achieved mainly by the dissociation rate constants, which vary by a factor of 600. These results show that the different effector·GTPase complexes form at similar rates and that the varying affinities are due to largely different dissociation rates leading to different lifetimes (defined as inverse dissociation rate constant) of the complexes. The lifetime of the low affinity Ras·RalGDS-RBD complex is about 0.1 s. In contrast, the Rap1·RalGDS-RBD complex is more stable with a lifetime of 10 s.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We have characterized a series of mutants to elucidate the reason for the specificity of the activation of RalGDS by Ras. A single point mutation within the RBD of RalGDS, which weakens the interaction to Ras more than 25-fold, almost completely disrupted the stimulation of RalGDS by Ras. On the contrary, a RalGDS protein, which was artificially targeted to the plasma membrane and lacked the RBD, could be activated by Ras, and the switch II region of Ras was involved in the activation of the effector. When Rap1A G12V is co-transfected with RalGDS, only the constructs containing the RBD are inhibited in their ability to activate RalA by Rap. Stopped-flow measurements demonstrate that the formation of the complex between effector RBDs and the GTP-form of Ras or Rap1 occurs in a comparable time frame, although large variations in the affinity exist. This binding specificity is achieved via largely differing dissociation rates. Active Rap1 can hold RalGDS-RBD especially long in the complexed state.

The observations, that Ras but not Rap1 is able to stimulate the RalGDS activity and that Rap1 binds a hundred times more tightly to RalGDS-RBD, encouraged us to elucidate the activation mechanism of RalGDS in more detail. In accordance with the data of Urano et al. (7), we could demonstrate with the mutant RalGDS K835A that the RBD of RalGDS is required for Ras-mediated activation. The major effect of this interaction is thought to be the recruitment of the effector to the plasma membrane. However, the observed stimulation of the membrane-targeted RalGDSDelta RBD-CAAX construct by Ras shows that recruitment of RalGDS to the plasma membrane is not the only mechanism of RalGDS activation. We were able to demonstrate this RBD-independent activation of RalGDS by Ras, because the recruitment of RalGDS by Ras via the RBD was separated from the subsequent activation. In contrast, RalGDS*-CAAX showed an elevated basal activity and could only be stimulated to a small degree. This effect might be explained by the fact that the GDP form of the Ras proteins still has some affinity for the effectors (40)2: The artificial membrane recruitment of RalGDS*-CAAX most likely facilitates the association between endogenous Ras in its GDP form and RalGDS*-CAAX, thereby explaining the high basal activity and the apparent unresponsiveness to Ras G12V. The nature of the additional function of Ras in this activation process involves the switch II region of Ras. It is conceivable that there are low affinity contacts between the switch II region of Ras and RalGDS, which enhance the exchange activity of the GEF domain. Such contacts were proposed in a complex between RalGDS RBD and Ras (38) but could not be confirmed by us (39). However, this activation scenario would parallel the findings for Raf-kinase and PI3K, which also become activated when bound to Ras (30, 41, 42). Alternatively, there could be an unidentified factor, which is controlled by Ras and acts positively on RalGDS.

The stimulatory effect observed in addition to membrane recruitment could rely on relieving inhibitory signals (37). Support for inhibitory signals acting on the GEF moiety of RalGDS comes from Rsc (12, 43). It has been demonstrated that transforming properties of this fusion protein are due to the Rgr region. Rgr lacks both N and C termini as observed in the other RalGDS family members and, therefore, may have lost an autoinhibitory signal.

The comparison of stopped-flow measurements of the complex formation between RBDs from RalGDS, Raf, and AF6 and the GTPases Ras and Rap1 revealed that the binding specificity is mainly achieved by variation of the dissociation rates. Conversely, for the Ras/Raf-RBD system it has recently been demonstrated that effector recognition by the GTP and GDP forms, respectively, is differentiated by the association process, i.e. the GTPase switch is designed to prevent an association between the GDP form of Ras and an effector (31). Taken together, recognition by the effector of GTPase switch position should be interpreted in terms of association rate constants in which Raf, the paradigm of a Ras effector, differs little from RalGDS. The lifetime of the complex between RalGDS-RBD and Ras is about 0.1 s. This should be long enough to enable other processes like small conformational changes and phosphorylation events. It is interesting that RalGDS is indeed phosphorylated (44). So far, no correlation between the activity of RalGDS and its phosphorylation state could be demonstrated.

Rap1 is described originally as a Ras antagonist (13-19). The observed slow dissociation rate between Rap1 and RalGDS-RBD could explain the Ras-antagonistic effect on a molecular level. Currently, no other Ras effector is described that has such a high affinity and, therefore, a slow dissociation rate constant as RalGDS-RBD and Rap1. We therefore speculate that inhibitory effects of Rap1 on Ras might be due mainly to a competition between these proteins for RalGDS. This hypothesis is corroborated by the necessity of the presence of RBD in RalGDS for Rap1 inhibition as observed in this study. In PC12 cells Ras signaling via Raf and PI3K mediates cell cycle arrest and differentiation of the cells into a neural cell type, but signaling via RalGDS leads to proliferation (10). These two opposing effects of Ras effector signaling require additional controls of the effectors. Sequestration of RalGDS by Rap1 would be one mechanism to control the flow of signals coming from Ras and supports observed Rap1 functions in differentiation (45-49). It should be noted that in NIH3T3 and Rat1 fibroblasts no inhibitory effect of Rap1 on RalA was observed (50). It is not clear if these differences are due to the sensitivity of the different assay systems or reflect special features of this kind of fibroblasts. Our data attempt to explain the influence of Rap1 on Ras transformation on a molecular level. However, they do not exclude RalGDS-independent functions of Rap, which might be transmitted by other effector proteins (20).

RalGDS belongs to the group of exchange factors with a Cdc25 homology domain. It has been demonstrated that another member of this family, Sos, is inhibited in its exchange activity via the C and N termini (51). This and our findings could indicate a general mechanism of GEFs homologous to Cdc25. In addition, findings with GEFs of other families of the small GTPases like the Dbl-homology domain containing Rho GEFs (52) and the Sec7-homology domain containing Arf GEFs (53), where PH domains are thought to regulate the exchange domain, give rise to a general picture in which GEF activity is down-modulated in the non-stimulated state. The physiological relevance of an actively inhibited GEF might be a decreased spontaneous activation of Ral.

The data presented here show the importance of the RBD in RalGDS for activation by Ras as well as for the inhibition by Rap1. In addition to RBD-mediated membrane recruitment by Ras, another component of activation, involving the switch II region of Ras, is indicated. Our kinetic data suggest a role of interaction dynamics for specific signal transduction. To further understand signal transmission by RalGDS, it will be necessary to determine the nature of the observed RBD-independent activation. Employing RalGDS variants, which are deficient of either Ras binding or activation, should also shed light on the benefits of an activation mechanism of RalGDS for signaling of Ras proteins under different physiological conditions.

    ACKNOWLEDGEMENTS

We thank Fried Zwartkruis, Rob Wolthuis, and Hans Bos for constructs and discussion. We also thank R. Berdeaux and C. Block for reagents, A. Wittinghofer for constant support, and Dan Irwin for critical comments on the manuscript.

    FOOTNOTES

* This work was supported by a grant from the Deutsche Forschungsgemeinschaft (SFB394) (to C. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at www.jbc.org) contains Fig. S1.

Dagger Present address: Howard Hughes Medical Institute, Mt. Zion Cancer Center, UCSF Box 0703, 3rd and Parnassus Ave., San Francisco, CA 94143.

§ To whom correspondence should be addressed: Tel.: 49-231-133-2160; Fax: 49-231-133-2199; E-mail: christian.herrmann@mpi-dortmund.mpg.de.

Published, JBC Papers in Press, December 17, 2001, DOI 10.1074/jbc.M110800200

2 C. Herrmann, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: PI3K, phosphatidylinositol 3-kinase; RalGDS, Ral guanine nucleotide dissociation stimulator; GEF, guanine-nucleotide exchange factor; RBD, Ras binding domain; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. McCormick, F., and Wittinghofer, A. (1996) Curr. Opin. Biotechnol. 7, 449-456[CrossRef][Medline] [Order article via Infotrieve]
2. Joneson, T., and Bar-Sagi, D. (1997) J. Mol. Med. 75, 587-593[CrossRef][Medline] [Order article via Infotrieve]
3. Sun, H., Tonks, N. K., and Bar-Sagi, D. (1994) Science 266, 285-288[Abstract/Free Full Text]
4. Jimenez, C., Jones, D. R., Rodriguezviciana, P., Gonzalezgarcia, A., Leonardo, E., Wennstrom, S., Vonkobbe, C., Toran, J. L., Borlado, L. R., Calvo, V., Copin, S. G., Albar, J. P., Gaspar, M. L., Diez, E., Marcos, M. A. R., Downward, J., Martinez, C., Merida, I., and Carrera, A. C. (1998) EMBO J. 17, 743-753[CrossRef][Medline] [Order article via Infotrieve]
5. Wolthuis, R. M. F., de Ruiter, N. D., Cool, R. H., and Bos, J. L. (1997) EMBO J. 16, 6748-6761[CrossRef][Medline] [Order article via Infotrieve]
6. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., and Downward, J. (1997) EMBO J. 16, 2783-2793[CrossRef][Medline] [Order article via Infotrieve]
7. Urano, T., Emkey, R., and Feig, L. A. (1996) EMBO J. 15, 810-816[Medline] [Order article via Infotrieve]
8. Franza, B. R., Maruyama, K., Garrels, J. I., and Ruley, H. E. (1986) Cell 44, 409-418[CrossRef][Medline] [Order article via Infotrieve]
9. Wood, K. W., Sarnecki, C., Roberts, T. M., and Blenis, J. (1992) Cell 68, 1041-1050[CrossRef][Medline] [Order article via Infotrieve]
10. Goi, T., Rusanescu, G., Urano, T., and Feig, L. A. (1999) Mol. Cell. Biol. 19, 1731-1741[Abstract/Free Full Text]
11. Wolthuis, R. M. F., and Bos, J. L. (1999) Curr. Opin. Genet. Dev. 9, 112-117[CrossRef][Medline] [Order article via Infotrieve]
12. D'Adamo, D. R., Novick, S., Kahn, J. M., Leonardi, P., and Pellicier, A. (1997) Oncogene 14, 1295-1305[CrossRef][Medline] [Order article via Infotrieve]
13. Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y., and Noda, M. (1989) Cell 56, 77-84[CrossRef][Medline] [Order article via Infotrieve]
14. Leach, S. D., Berger, D. H., Davidson, B. S., Curley, S. A., and Tainsky, M. A. (1998) Pancreas 16, 491-498[Medline] [Order article via Infotrieve]
15. Damak, S., Harnboonsong, Y., George, P. M., and Bullock, D. W. (1996) Mol. Carcinog. 17, 84-91[Medline] [Order article via Infotrieve]
16. Kondoh, N., Noda, M., Fisher, R. J., Schweinfest, C. W., Papas, T. S., Kondoh, A., Samuel, K. P., and Oikawa, T. (1996) Biochim. Biophys. Acta 1313, 41-46[Medline] [Order article via Infotrieve]
17. Burney, T. L., Rockove, S., Eiseman, J. L., Jacobs, S. C., and Kyprianou, N. (1994) Prostate 25, 177-188[Medline] [Order article via Infotrieve]
18. Sakoda, T., Kaibuchi, K., Kishi, K., Kishida, S., Doi, K., Hoshino, M., Hattori, S., and Takai, Y. (1992) Oncogene 7, 1705-1711[Medline] [Order article via Infotrieve]
19. Caamano, J., DiRado, M., Iizasa, T., Momiki, S., Fernandes, E., Ashendel, C., Noda, M., and Klein-Szanto, A. J. (1992) Mol. Carcinog. 6, 252-259[Medline] [Order article via Infotrieve]
20. Bos, J. L., de Rooij, J., and Reedquist, K. A. (2001) Nature Rev. 2, 369-377
21. Herrmann, C., Horn, G., Spaargaren, M., and Wittinghofer, A. (1996) J. Biol. Chem. 271, 6794-6800[Abstract/Free Full Text]
22. Kishida, S., Koyama, S., Matsubara, K., Kishida, M., Matsuura, Y., and Kikuchi, A. (1997) Oncogene 15, 2899-2907[CrossRef][Medline] [Order article via Infotrieve]
23. Matsubara, K., Kishida, S., Matsuura, Y., Kitayama, H., Noda, M., and Kikuchi, A. (1999) Oncogene 18, 1303-1312[CrossRef][Medline] [Order article via Infotrieve]
24. Beranger, F., Goud, B., Tavitian, A., and de Gunzberg, J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1606-1610[Abstract/Free Full Text]
25. Pizon, V., Desjardins, M., Bucci, C., Parton, R. G., and Zerial, M. (1994) J. Cell Sci. 107, 1661-1670[Abstract]
26. Maridonneau-Parini, I., and De Gunzburg, J. (1992) J. Biol. Chem. 267, 6396-6402[Abstract/Free Full Text]
27. Berger, G., Quarck, R., Tenza, D., Levy-Toledano, S., De, Gunzburg, J., and Cramer, E. M. (1994) Br. J. Haematol. 88, 372-382[Medline] [Order article via Infotrieve]
28. Feig, L. A., Urano, T., and Cantor, S. (1996) Trends Biochem. Sci. 21, 438-441[CrossRef][Medline] [Order article via Infotrieve]
29. Morrison, D. K., and Cutler, R. E. (1997) Curr. Opin. Cell Biol. 9, 174-179[CrossRef][Medline] [Order article via Infotrieve]
30. Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., and Williams, R. L. (2000) Cell 103, 931-943[CrossRef][Medline] [Order article via Infotrieve]
31. Sydor, J. R., Engelhard, M., Wittinghofer, A., Goody, R. S., and Herrmann, C. (1998) Biochemistry 37, 14292-14299[CrossRef][Medline] [Order article via Infotrieve]
32. Picard, V., Ersdal-Badju, E., Lu, A., and Bock, S. C. (1994) Nucleic Acids Res. 22, 2587-2591[Abstract/Free Full Text]
33. Tucker, J., Sczakiel, G., Feuerstein, J., John, J., Goody, R. S., and Wittinghofer, A. (1986) EMBO J. 5, 1351-1358[Medline] [Order article via Infotrieve]
34. John, J., Sohmen, R., Feuerstein, J., Linke, R., Wittinghofer, A., and Goody, R. S. (1990) Biochemistry 29, 6058-6065[CrossRef][Medline] [Order article via Infotrieve]
35. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
36. Linnemann, T., Geyer, M., Jaitner, B. K., Block, C., Kalbitzer, H. R., Wittinghofer, A., and Herrmann, C. (1999) J. Biol. Chem. 274, 13556-13562[Abstract/Free Full Text]
37. Geyer, M., Herrmann, C., Wohlgemuth, S., Wittinghofer, A., and Kalbitzer, H. R. (1997) Nat. Struct. Biol. 4, 694-699[CrossRef][Medline] [Order article via Infotrieve]
38. Huang, L., Hofer, F., Martin, G. S., and Kim, S. H. (1998) Nat. Struct. Biol. 5, 422-426[CrossRef][Medline] [Order article via Infotrieve]
39. Vetter, I. R., Linnemann, T., Wohlgemuth, S., Geyer, M., Kalbitzer, H. R., Herrmann, C., and Wittinghofer, A. (1999) FEBS Let. 451, 175-180[CrossRef][Medline] [Order article via Infotrieve]
40. Herrmann, C., Martin, G. A., and Wittinghofer, A. (1995) J. Biol. Chem. 270, 2901-2905[Abstract/Free Full Text]
41. Stokoe, D., and McCormick, F. (1997) EMBO J. 16, 2384-2396[CrossRef][Medline] [Order article via Infotrieve]
42. Tamada, M., Hu, C. D., Kariya, K., Okada, T., and Kataoka, T. (1997) Oncogene 15, 2959-2964[CrossRef][Medline] [Order article via Infotrieve]
43. Hernandez-Munoz, I., Malumbres, M., Leonardi, P., and Pellicer, A. (2000) Oncogene 19, 2745-2757[CrossRef][Medline] [Order article via Infotrieve]
44. Albright, C. F., Giddings, B. W., Liu, J., Vito, M., and Weinberg, R. A. (1993) EMBO J. 12, 339-347[Medline] [Order article via Infotrieve]
45. Hariharan, I. K., Carthew, R. W., and Rubin, G. M. (1991) Cell 67, 717-722[CrossRef][Medline] [Order article via Infotrieve]
46. Chant, J., Corrado, K., Pringle, J. R., and Herskowitz, I. (1991) Cell 65, 1213-1224[CrossRef][Medline] [Order article via Infotrieve]
47. Rebstein, P. J., Cardelli, J., Weeks, G., and Spiegelman, G. B. (1997) Exp. Cell Res. 231, 276-283[CrossRef][Medline] [Order article via Infotrieve]
48. Ito, S., Matsui, Y., Toh-e, A., Harashima, T., and Inoue, H. (1997) Mol. Gen. Genet. 255, 429-437[CrossRef][Medline] [Order article via Infotrieve]
49. Yoshida, Y., Kawata, M., Miura, Y., Musha, T., Sasaki, T., Kikuchi, A., and Takai, Y. (1992) Mol. Cell. Biol. 12, 3407-3414[Abstract/Free Full Text]
50. Zwartkruis, F. J. T., Wolthuis, R. M. F., Nabben, N. M. J. M., Franke, B., and Bos, J. L. (1998) EMBO J. 17, 5905-5912[CrossRef][Medline] [Order article via Infotrieve]
51. Corbalan-Garcia, S., Margarit, S. M., Galron, D., Yang, S. S., and Barsagi, D. (1998) Mol. Cell. Biol. 18, 880-886[Abstract/Free Full Text]
52. Han, J. W., Lubyphelps, K., Das, B., Shu, X. D., Xia, Y., Mosteller, R. D., Krishna, U. M., Falck, J. R., White, M. A., and Broek, D. (1998) Science 279, 558-560[Abstract/Free Full Text]
53. Klarlund, J. K., Rameh, L. E., Cantley, L. C., Buxton, J. M., Holik, J. J., Sakelis, C., Patki, V., Corvera, S., and Czech, M. P. (1998) J. Biol. Chem. 273, 1859-1862[Abstract/Free Full Text]
54. van Weering, D. H. J., and Bos, J. L. (1997) J. Biol. Chem. 272, 249-254[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
M. G. Rondaij, R. Bierings, E. L. van Agtmaal, K. A. Gijzen, E. Sellink, A. Kragt, S. S. G. Ferguson, K. Mertens, M. J. Hannah, J. A. van Mourik, et al.
Guanine exchange factor RalGDS mediates exocytosis of Weibel-Palade bodies from endothelial cells
Blood, July 1, 2008; 112(1): 56 - 63.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. C. He, I. Gomes, T. Nguyen, G. Jayaram, P. T. Ram, L. A. Devi, and R. Iyengar
The G{alpha}o/i-coupled Cannabinoid Receptor-mediated Neurite Outgrowth Involves Rap Regulation of Src and Stat3
J. Biol. Chem., September 30, 2005; 280(39): 33426 - 33434.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Ling, T. Zhu, and P. E. Lobie
Src-CrkII-C3G-dependent Activation of Rap1 Switches Growth Hormone-stimulated p44/42 MAP Kinase and JNK/SAPK Activities
J. Biol. Chem., July 11, 2003; 278(29): 27301 - 27311.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
277/10/7831    most recent
M110800200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linnemann, T.
Right arrow Articles by Herrmann, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linnemann, T.
Right arrow Articles by Herrmann, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement